Oncotarget

Research Papers:

Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells

Jiajin Li, Hui Yan, Li Zhao, Wenzhi Jia, Hao Yang, Liu Liu, Xiang Zhou, Ping Miao, Xiaoguang Sun, Shaoli Song, Xiaoping Zhao, Jianjun Liu and Gang Huang _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:52392-52403. https://doi.org/10.18632/oncotarget.10721

Metrics: PDF 2511 views  |   HTML 2784 views  |   ?  


Abstract

Jiajin Li1,2,*, Hui Yan1,2,*, Li Zhao1,2, Wenzhi Jia1,2, Hao Yang3, Liu Liu1,2, Xiang Zhou1,2, Ping Miao1,2, Xiaoguang Sun1,2, Shaoli Song1,2, Xiaoping Zhao1,2, Jianjun Liu1,2, Gang Huang1,2,3,4

1Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China

2Institute of Clinical Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China

3Institute of Health Sciences, Shanghai Jiao Tong University School of Medicine & Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200025, China

4Shanghai University of Medicine and Health Sciences, Shanghai 201318, China

*These authors have contributed equally to this work

Correspondence to:

Gang Huang, email: [email protected]

Keywords: lung cancer, gefitinib, SREBP, chemotherapy, lipid metabolism

Received: October 12, 2015     Accepted: June 29, 2016     Published: July 20, 2016

ABSTRACT

The clinical success of EGFR inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance. Here, we show that inhibition of SREBP increase gefitinib sensitivity in vitro and in vivo. Interference of SREBP1 binding partner MARVELD1 potentiate the therapeutic effect of gefitinib as well. Mechanistically, SREBP inhibition decreases the cell membrane fluidity, results in a decreased tyrosine phosphorylation of EGFR. Therefore, targeting lipid metabolism combined with EGFR-TKIs is potentially a novel therapeutic strategies for cancer treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10721